Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 6.5% – Should You Sell?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares fell 6.5% during mid-day trading on Friday . The company traded as low as $22.78 and last traded at $23.4450. 63,161 shares were traded during mid-day trading, a decline of 82% from the average session volume of 351,048 shares. The stock had previously closed at $25.08.

Key Headlines Impacting Pulse Biosciences

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Q4 EPS beat analyst expectations — Pulse reported a loss of $0.26 per share vs. consensus -$0.32, beating estimates and showing a smaller-than-expected loss. This helped limit downside after the print. Read More.
• Positive Sentiment: Clinical/business update: company highlighted strong procedural results for its endocardial nPulse catheter (100% freedom from AF at 6 months, 96% procedural success), supporting long‑term product potential and commercialization story. Read More.
• Neutral Sentiment: Investor outreach: Pulse will present at the 46th Annual TD Cowen Healthcare Conference — useful for visibility and investor Q&A but not an immediate revenue driver. Read More.
• Neutral Sentiment: Inducement equity grants: the board awarded equity inducements to two new employees under Nasdaq Rule 5635(c)(4). Standard hiring practice; could be seen as modestly dilutive over time but routine. Read More.
• Negative Sentiment: Revenue missed expectations — reported revenue was effectively flat/negative ($-0.09M) vs. the consensus ~$0.23M, raising near-term commercialization and cash‑flow concerns for some investors. Read More.
• Negative Sentiment: Insider selling: recent filings show insiders sold roughly $0.94M combined in two transactions, which investors may interpret as a negative signal on near‑term insider conviction. Read More. Read More.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on PLSE shares. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday. Oppenheimer restated an “outperform” rating and issued a $30.00 price objective on shares of Pulse Biosciences in a research note on Friday. Finally, Mizuho set a $30.00 target price on Pulse Biosciences in a research report on Friday, February 6th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Pulse Biosciences has an average rating of “Hold” and a consensus target price of $30.00.

Pulse Biosciences Stock Performance

The stock has a market cap of $1.45 billion, a PE ratio of -19.83 and a beta of 1.77. The firm’s 50-day moving average is $16.35 and its 200 day moving average is $16.08.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.06. The business had revenue of ($0.09) million during the quarter, compared to analyst estimates of $0.23 million.

Insider Transactions at Pulse Biosciences

In other Pulse Biosciences news, insider Kevin Patrick Danahy sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $23.53, for a total transaction of $470,600.00. Following the completion of the sale, the insider directly owned 43,298 shares of the company’s stock, valued at $1,018,801.94. This represents a 31.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 80,000 shares of company stock valued at $1,876,200. Insiders own 74.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its holdings in shares of Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after purchasing an additional 680 shares during the period. Tower Research Capital LLC TRC increased its stake in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after buying an additional 2,156 shares during the period. Russell Investments Group Ltd. raised its position in Pulse Biosciences by 13.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after buying an additional 619 shares during the last quarter. KLP Kapitalforvaltning AS lifted its stake in shares of Pulse Biosciences by 136.0% in the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock worth $104,000 after acquiring an additional 3,400 shares during the period. Finally, AlphaQuest LLC boosted its holdings in shares of Pulse Biosciences by 184.5% in the second quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock valued at $134,000 after acquiring an additional 5,748 shares in the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.